Recommendations from Clinical Practice Guidelines about Managing Patients with Hypertension.

SOA: South Africa; IND: India; POL: Poland; MAL: Malaysia; EUR: Europe; JAP: Japan; LAT: Latin America; AUS: Australia; CAN: Canada and SAU: Saudi Arabia and NICE (The UK's National Institute for Health and Clinical Excellence). NR: not reported. A: angiotensin converting enzyme inhibitor (ACEI), or angiotensin receptor blockers (ARB), C: calcium channel blocker (CCB), D: Diuretic.
1And if SBP>150 and or DBP>95- treat.
2If the SBP> or  = 140 mm Hg or DBP> or  = 90 mm Hg across 5 visits.
3if SBP = 120–159 mmHg AND/OR DBP = 80–99 mmHg.
4If, at visit 2 within one month, SBP is > or  = 140 mm Hg and/or DBP is > or  = 90 mm Hg.
5If SBP = 120–159 mmHg AND/OR DBP = 80–99 mmHg with high risk or if SBP 160 mmHg AND/OR DBP 100 mmHg regardless of risk.
6NICE CPG favored A for those below 55 years and C, D, for those aged 55 years or older and for black patients.
7Yes if SBP>10 mmHg above target.
8Recommended in at least certain high risk groups.
9Recommended for those with atherosclerotic renal artery stenosis only.
10No target level stated.
11A1c<6.5 mmol/L.
12A1c between 6.5–7% in patients with HTN, DM and nephropathy.
13Referred to previous guideline version.
14Every 3–6 months;
15Every 3 months for high risk patients and every 6 months for low risk patients;
16Every 3 months for the first year then 6-monthly thereafter;
17Once a year.
18For pheochromocytoma cases only.